Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

被引：5
|
作者：
Ho, Alan Loh
Sherman, Eric Jeffrey
Fury, Matthew G.
Baxi, Shrujal S.
Haque, Sofia
Sima, Camelia S.
Antonescu, Cristina R.
Katabi, Nora
Pfister, David G.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.6093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6093
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
    Bang, A.
    Mahmood, U.
    Chen, Y. H.
    Mak, R. H.
    Lorch, J.
    Hanna, G. J.
    Sridharan, V.
    Busse, P. M.
    Willers, H.
    Mamon, H. J.
    Yoo, H. J.
    Pai, S. I.
    Wirth, L.
    Haddad, R. I.
    Chau, N.
    Schoenfeld, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E363 - E363
  • [32] LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS
    Bang, Andrew
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S26 - S27
  • [33] A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
    Goncalves, Priscila Hermont
    Kummar, Shivaani
    Siu, Lillian L.
    Hansen, Aaron Richard
    Savvides, Panayiotis
    Sukari, Ammar
    Chao, Joseph
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Smith, Daryn W.
    Casetta, Lindsay
    Boerner, Scott Anthony
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Fetten, James Vincent
    Michel, Loren S.
    Kriplani, Anuja
    Morris, Luc
    Ostrovnaya, Irina
    Katabi, Nora
    Haque, Sofia
    Tran, Crystal
    Azar, Julian
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
    Swiecicki, Paul L.
    Zhao, Lili
    Belile, Emily
    Sacco, Assuntina G.
    Chepeha, Douglas B.
    Dobrosotskaya, Irina
    Spector, Matthew
    Shuman, Andrew
    Malloy, Kelly
    Moyer, Jeffrey
    McKean, Erin
    McLean, Scott
    Wolf, Gregory T.
    Eisbruch, Avraham
    Prince, Mark
    Bradford, Carol
    Carey, Thomas
    Worden, Francis P.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1248 - 1256
  • [36] A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
    Paul L. Swiecicki
    Lili Zhao
    Emily Belile
    Assuntina G. Sacco
    Douglas B. Chepeha
    Irina Dobrosotskaya
    Matthew Spector
    Andrew Shuman
    Kelly Malloy
    Jeffrey Moyer
    Erin McKean
    Scott McLean
    Gregory T. Wolf
    Avraham Eisbruch
    Mark Prince
    Carol Bradford
    Thomas Carey
    Francis P. Worden
    Investigational New Drugs, 2015, 33 : 1248 - 1256
  • [37] Second-line systemic therapy in patients with recurrent or metastatic adenoid cystic carcinoma
    Kadowaki, Shigenori
    Nakazawa, Taiko
    Ogata, Takatsugu
    Matsubara, Yuki
    Nozawa, Kazuki
    Kato, Kyoko
    Narita, Yukiya
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Ando, Masashi
    Hanai, Nobuhiro
    Muro, Kei
    ANNALS OF ONCOLOGY, 2021, 32 : S312 - S312
  • [38] Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands
    Agulnik, Mark
    Cohen, Ezra W. E.
    Cohen, Roger B.
    Chen, Eric X.
    Vokes, Everett E.
    Hotte, Sebastien J.
    Winquist, Eric
    Laurie, Scott
    Hayes, D. Neil
    Dancey, Janet E.
    Brown, Shirley
    Pond, Gregory R.
    Lorimer, Ian
    Daneshmand, Manijeh
    Ho, James
    Tsao, Ming-Sound
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3978 - 3984
  • [39] Phase 2 Study of Apatinib, A Novel VEGFR Inhibitor in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Preliminary Results
    Dou, S.
    Zhang, L.
    Li, R.
    Zhu, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1378 - 1379
  • [40] A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.
    Kang, Hyunseok
    Ho, Alan Loh
    Muzaffar, Jameel
    Bowles, Daniel W.
    Kim, Sung-Bae
    Ahn, Myung-Ju
    Hanna, Glenn J.
    Worden, Francis P.
    Yun, Tak
    Norton, Steven
    Sankar, Neil
    Keam, Bhumsuk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345